PDCD1 and colonic neoplasm: In addition, the inhibition of glutamine metabolism by a competitive antagonist of transmembrane glutamine flux or a GLS inhibitor, in combination with anti-PD-1 or anti-PD-L1 antibodies, has been shown to reduce tumor growth in breast and colon cancer mouse models to a greater extent than monotherapies (181, 187).